Track Dovato price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Dovato Costs $2,910.00 Per Claim
Dovato (Dolutegravir/Lamivudine) is used to treat hiv. According to CMS Medicare Part D spending data, the program spent $1.2B on this drug, covering 36,000 beneficiaries across 424,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Dolutegravir/Lamivudine or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Dovato increased by +32.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Dovato (Dolutegravir/Lamivudine) costs an average of $2,910.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $34,278.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Dovato averages $2,910.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Dovato reflects in our Medicare Part D average of $2,910.00 per claim. Switching to generic Dolutegravir/Lamivudine typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Dovato, but coverage varies by formulary tier. Insurers typically prefer generic Dolutegravir/Lamivudine (Tier 1, lowest copay) over brand-name Dovato (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Dolutegravir/Lamivudine is the single biggest cost reducer if your prescriber is open to it.
Brand-name Dovato costs more than generic Dolutegravir/Lamivudine primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Dovato (Dolutegravir/Lamivudine) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Dolutegravir/Lamivudine.
Medicare Part D spent $1.2B on Dovato, covering 36,000 beneficiaries across 424,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Dolutegravir/Lamivudine, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Dovato's Medicare Pricing
Dovato averages $2,910.00 per Part D claim — a high-cost brand medication, well above the commodity-generic range but below the specialty/biologic tier. A price in this band usually signals an on-patent brand with no generic equivalent, or a brand that holds share through prescriber and patient preference even where a generic exists. For hiv, the gap between this price and a same-class alternative is where the real savings conversation tends to live.
As a Medicare line item, Dovato is enormous: $1.2B in total Part D spending across 424,000 claims for 36,000 beneficiaries. At that scale the total is a product of both reach and price — a drug this widely prescribed at this cost is exactly the kind of molecule that draws CMS price-negotiation attention and PBM formulary leverage. The per-beneficiary figure, roughly $34K a year, is what translates the aggregate into an individual cost picture.
Because a generic version of Dolutegravir/Lamivudine is on the market, the realistic savings path for Dovato is straightforward: the generic is therapeutically equivalent and typically costs a fraction of the brand. The friction is usually prescribing habit rather than availability — patients can ask the prescriber to write for the generic, and most plans already steer to it with a lower copay tier. That single switch usually beats coupons, assistance programs, and pharmacy shopping combined.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $2,910.00 as a consistent Medicare-program benchmark for Dovato, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Compare costs for other hiv medications
Compare 8 drugs in the HIV Antiretrovirals class
See every ViiV Healthcare drug tracked by Medicare Part D
Top prescription drugs by Medicare spending
Drugs losing patent protection soon
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.